Hepatology billing hinges on percutaneous liver biopsy 47000 with imaging-guided add-on 47001 and the 26/TC split on the imaging component, paracentesis 49000 with fluid-administration add-on 49083, HCC surveillance ultrasound 76770/76700 with AFP, and transplant-eval E/M workups. Add MELD/MELD-Na documentation and antiviral J-code capture — and general billers miss revenue on every encounter. MedFactor delivers hepatology-specific RCM that protects every claim.
From general hepatology and viral hepatitis to fatty liver, cirrhosis, transplant, and liver tumor care, we tailor billing to the coding rules of every hepatology subspecialty.
Liver biopsy 47000/47001, transient elastography 91150/76789, and chronic liver disease E/M with staging documentation.
Antiviral J-code drug capture (Mavyret, Epclusa, Harvoni), B18/B19 diagnosis sequencing, and HCV clearance testing.
Fibrosis staging with elastography, biopsy 47000 with 26/TC imaging splits, and metabolic-workup capture.
Paracentesis 49000 with fluid-administration add-on 49083, variceal screening, and MELD/MELD-Na documentation.
Multi-disciplinary transplant-eval E/M workups, TIPS imaging, and Z94 transplant-status coordination with facility billing.
HCC surveillance ultrasound 76770/76700 with AFP lab, C22 liver cancer diagnosis, and tumor-board E/M capture.
Percutaneous liver biopsy bills as a base procedure 47000 plus an imaging-guided add-on 47001 — and the imaging component must carry the right 26/TC modifier or it's denied. Pair that with transient elastography, paracentesis add-ons, HCC surveillance, and the transplant-eval workup, and this is the largest source of hepatology denials.
One liver-biopsy session bills 47000 for the percutaneous approach, 47001 as the add-on when imaging guides it, and the imaging professional/technical component must be split with modifier 26 or TC.
Hepatology billing is governed by liver-biopsy add-on rules, imaging 26/TC component splits, paracentesis bundling, and antiviral J-code capture that general billing companies cannot navigate effectively.
Percutaneous liver biopsy billed without the 47001 imaging-guided add-on, and the imaging guidance dropped because the 26/TC split wasn't applied per payer rules.
Therapeutic paracentesis 49000 billed without the 49083 fluid-administration add-on, or denied as bundled when documentation of fluid management is missing.
Cirrhosis surveillance ultrasound 76770/76700 with AFP denied for frequency-limit overage or without the cirrhosis diagnosis that supports screening.
Antiviral agents (Mavyret, Epclusa, Harvoni) under-captured as pharmacy-only, with J-code or NDC billing and the B18/B19 diagnosis sequencing missed.
Multi-disciplinary transplant-eval E/M workups, TIPS imaging coordination, and Z94 transplant-status coordination billed without the supporting MELD/MELD-Na documentation.
Same-day E/M with paracentesis or liver biopsy denied when modifier 25 isn't appended or when the E/M documentation doesn't support a separately identifiable service.
Quick reference for the most frequently used codes in hepatology and liver-disease billing and coding.
| Code | Description | Common Use |
|---|---|---|
| 47000 | Percutaneous liver biopsy | Base biopsy procedure |
| 47001 | Liver biopsy, imaging-guided add-on | Ultrasound/CT guidance add-on |
| 49000 | Paracentesis, abdominal (diagnostic/therapeutic) | Cirrhotic ascites drainage |
| 49083 | Paracentesis fluid administration (add-on) | Peritoneal fluid management |
| 91150 | Transient elastography (liver stiffness) | Non-invasive fibrosis staging |
| 76789 | Ultrasound elastography of liver | SWE/ARFI imaging stiffness |
| 76770 | US abdomen, retroperitoneal complete | HCC surveillance imaging |
| 76700 | US abdomen complete | Liver surveillance / screening |
| 76881 | US extremity complete (vessel eval) | Variceal / vessel assessment |
| 91200 | Liver function testing panel | Hepatic function assessment |
| Code | Description | Clinical Context |
|---|---|---|
| B18.x | Chronic viral hepatitis | Hepatitis B/C chronic infection |
| B19.x | Unspecified viral hepatitis | Acute/unspecified viral hepatitis |
| K70.x | Alcoholic liver disease | Alcohol-related liver disease |
| K71.x | Toxic (drug-induced) liver disease | Drug-induced liver injury |
| K72.x | Hepatic failure | Acute/chronic hepatic failure |
| K74.x | Fibrosis and cirrhosis of liver | Fibrosis / cirrhosis staging |
| K76.x | Other diseases of liver | NASH / NAFLD / other liver |
| C22.x | Malignant neoplasm of liver / intrahepatic bile ducts | HCC / liver cancer |
| Z94.4 | Liver transplant status | Post-transplant status |
| R18.x | Ascites | Cirrhotic ascites / paracentesis |
| Modifier | Description | Hepatology Application |
|---|---|---|
| 26 | Professional component | Imaging guidance / elastography interpretation |
| TC | Technical component | Imaging equipment / elastography testing |
| 25 | Separate E/M same day | E/M with same-day biopsy / paracentesis |
| 59 | Distinct procedural service | Distinct HCC surveillance imaging same session |
| 51 | Multiple procedures | Multiple biopsies / procedures same session |
| 22 | Increased procedural service | Unusually complex biopsy / transplant eval |
| 52 | Reduced services | Partial / incomplete procedure |
| 50 | Bilateral procedure | Bilateral vessel / imaging procedures |
Comprehensive revenue cycle management designed specifically for hepatology and liver-disease practices.
Specialty coders handle liver biopsy 47000/47001, 26/TC imaging splits, paracentesis 49000/49083, and HCC surveillance with accuracy.
Biopsy add-on defense, imaging component-split corrections, antiviral J-code appeals, and transplant-eval documentation.
Pre-procedure authorization for liver biopsy, transient elastography, antiviral therapy, and transplant-eval workups.
Prioritized follow-up on aged biopsy, paracentesis, and antiviral claims with strategic payer escalation to maximize recovery.
Regular audits focused on 47001 add-on capture, 26/TC splits, modifier 25 with procedures, and HCC surveillance frequency.
Real-time dashboards tracking biopsy add-on capture, antiviral J-code volume, MELD/MELD-Na staging, and physician productivity.
Understanding the most common denial reasons is the first step to preventing them on biopsy, paracentesis, and liver-tumor claims.
Imaging-guided biopsy billed without the 47001 add-on, and the imaging guidance dropped for a missing 26/TC split.
47001 add-on sequencing with the correct 26/TC imaging component split per payer rules.
Therapeutic paracentesis 49000 billed without the 49083 fluid-administration add-on or denied as bundled.
49083 add-on capture with fluid-management documentation supporting the separately reportable service.
Cirrhosis surveillance ultrasound 76770/76700 with AFP denied for frequency-limit overage without the cirrhosis diagnosis.
Surveillance frequency tracking with K74 cirrhosis diagnosis and AFP lab supporting each screening claim.
Hepatitis C antivirals (Mavyret, Epclusa, Harvoni) under-captured as pharmacy-only without the B18/B19 diagnosis sequencing.
J-code / NDC drug capture with correct B18/B19 diagnosis sequencing and HCV clearance testing.
Identifying and plugging these common revenue leakage points can significantly improve your practice's bottom line.
Imaging-guided liver biopsy billed without the 47001 add-on, losing the guidance component.
Fluid-administration add-on 49083 not billed with therapeutic paracentesis 49000.
Imaging guidance technical or professional component not split where the payer requires 26/TC.
Cirrhosis surveillance ultrasound denied beyond frequency limits without the supporting K74 diagnosis.
See how hepatology-specific revenue cycle management transforms your practice's financial performance.
A structured onboarding process designed to deliver measurable improvements within the first 90 days.
Review of hepatology billing operations, 47001 add-on capture, 26/TC splits, and revenue cycle baseline.
EMR and transplant-eval system integration, dedicated hepatology billing team, and payer enrollment verification.
Full billing with real-time claim submission, modifier verification, and denial prevention protocols.
Performance review against baseline, workflow optimization, and documented revenue improvement.
How our hepatology-specific approach compares to in-house billing and general medical billing companies.
| Capability | In-House Team | General Billing Co. | MedFactor Hepatology |
|---|---|---|---|
| Liver biopsy 47001 add-on capture | Inconsistent | ✕ | ✓ |
| Imaging guidance 26/TC splits | ✕ | ✕ | ✓ |
| Paracentesis 49083 add-on capture | Inconsistent | ✕ | ✓ |
| HCC surveillance frequency tracking | Manual | Partial | ✓ |
| Antiviral J-code / NDC capture | ✕ | Partial | ✓ |
| Transplant-eval E/M with MELD documentation | Inconsistent | ✕ | ✓ |
| Modifier 25 with same-day procedures | Inconsistent | Partial | ✓ |
| Biopsy add-on capture reporting | ✕ | ✕ | ✓ |
| Dedicated hepatology billing team | ✕ | ✕ | ✓ |
Our team combines deep hepatology billing expertise with the technology and processes to deliver consistent, measurable results for liver-disease, viral hepatitis, and transplant-eval practices.
Discover exactly where your hepatology practice is losing revenue. Our no-obligation audit analyzes your liver-biopsy add-on capture, 26/TC splits, and antiviral J-code compliance.
Real results from hepatology and liver-disease practices that partnered with MedFactor for specialty revenue cycle management.
A viral hepatitis treatment clinic was billing Mavyret and Epclusa as pharmacy-only and dropping the B18/B19 diagnosis sequencing. MedFactor implemented J-code / NDC capture with correct diagnosis sequencing, recovering substantial drug revenue in eight months.
A cirrhosis-focused practice was billing therapeutic paracentesis 49000 without the 49083 fluid-administration add-on and dropping imaging 26/TC splits. MedFactor implemented the add-on and component-split protocols, recovering per-session revenue.
A liver transplant-eval center was billing multi-disciplinary E/M workups without the MELD/MELD-Na documentation that supports severity. MedFactor implemented staging-driven documentation that protected transplant-eval E/M revenue.
No matter where your hepatology practice operates, our team understands the payer landscape and regulatory requirements in your region.
Deep coding knowledge across Medicare, Medicaid, and all major commercial payers for hepatology services.
Imaging guidance and elastography 26/TC component rules applied correctly across all 50 states.
Facility and professional billing coordination across hospital-based transplant-eval and TIPS procedures.
State Medicaid antiviral prior-auth and J-code / NDC capture for hepatitis C direct-acting agents.
Common questions from hepatology and liver-disease practices considering MedFactor's specialty RCM services.
Percutaneous liver biopsy is billed as 47000 for the base procedure. When imaging (ultrasound or CT) guides the biopsy, the add-on code 47001 is appended for the imaging guidance in the same session. The imaging guidance component itself is separately reportable with modifier 26 (professional interpretation) or TC (technical equipment) depending on who performs and interprets it. We capture 47000 plus 47001 on every imaging-guided biopsy and apply the correct 26/TC split on the imaging so neither the biopsy add-on nor the imaging component revenue is lost to a global-only denial.
Therapeutic or diagnostic abdominal paracentesis is billed as 49000. When peritoneal fluid administration or management occurs in the same session, the add-on code 49083 is appended. Some NCCI edits restrict billing 49083 without the supporting fluid-management documentation, so we verify the documentation before submission. We capture 49000 plus the 49083 add-on where fluid administration is documented, preserving the separately reportable service payment; without the add-on, the fluid-management work is bundled and the revenue is lost.
For cirrhosis patients under hepatocellular carcinoma (HCC) surveillance, the recommended screening is a liver ultrasound (76700 complete abdomen, or 76770 retroperitoneal) typically every six months, paired with an alpha-fetoprotein (AFP) lab test. We pair each surveillance claim with the K74 cirrhosis diagnosis that supports screening and track surveillance frequency per patient against payer limits. When the ultrasound is performed on the same day as a separately identifiable E/M, modifier 25 is appended to the E/M so the imaging is paid rather than denied as bundled.
Hepatitis C direct-acting antivirals (such as Mavyret, Epclusa, and Harvoni) are captured either as pharmacy claims with the correct NDC or as J-code / HCPCS drug billing depending on the site of service and payer. The B18 (chronic viral hepatitis) or B19 (unspecified viral hepatitis) diagnosis is sequenced first to support medical necessity, with the HCV clearance testing documented. We verify the payer's pharmacy vs medical benefit routing for each agent and capture the drug with the correct diagnosis sequencing so antiviral revenue isn't lost to a pharmacy-only submission.
Liver transplant evaluation is a multi-disciplinary workup billed with the appropriate E/M level (typically 9924x inpatient consultation or office E/M codes depending on setting), with TIPS or related imaging (such as 37242 transcatheter placement) billed separately when performed. The MELD or MELD-Na score and severity documentation support the medical necessity of the eval. Z94.4 liver transplant status is used for post-transplant follow-up. We coordinate the professional and facility billing across the transplant-eval encounter and document MELD/MELD-Na severity so the E/M workup is paid rather than denied for missing documentation.
Modifier 25 is appended to the E/M code when a separately identifiable evaluation and management service is performed on the same day as a procedure such as liver biopsy 47000, paracentesis 49000, or HCC surveillance imaging. The E/M documentation must support a significant, separately identifiable service beyond the pre- and post-procedure work inherent to the procedure. We audit each same-day E/M for the supporting documentation and append modifier 25 where appropriate, so the E/M is paid rather than denied as bundled into the procedure.
MedFactor applies the same code-level precision across the full practice spectrum. See how we bill these related specialties.
CPT®, ICD-10, HCPCS, and modifier codes referenced on this page reflect the current code sets and are subject to annual updates — always verify against the current-year fee schedule before submission. KPIs and case-study figures shown are representative benchmarks, not guarantees of individual practice results.
Your hepatology practice deserves billing partners who know liver-biopsy 47001 add-on coding, imaging 26/TC splits, paracentesis 49083, and transplant-eval documentation — and code every claim correctly. Let MedFactor show you what specialty RCM can do.